Strohmaier W, Redl H, Schlag G, Inthorn D
Crit Care Med. 1987 Aug;15(8):757-60. doi: 10.1097/00003246-198708000-00009.
The activation of macrophages is accompanied by release of 2-amino-4-oxo-6(D-erythro-1',2',3'-trihydroxypropyl)-dihydropterid ine (D-erythro-neopterin). The neopterin levels of 21 patients were measured with radioimmunoassay. The patients were classified according to the clinical course and outcome. We found highly significant differences between survivors and nonsurvivors for each of the evaluated days of the observation period. In addition to a sustained increase, patients with fatal outcome always showed a higher percentage of neopterin levels (88.2 +/- 28 [SD]%) exceeding the upper confidence limit (27.4 nmol/L) than survivors (31.8 +/- 29.9%). We conclude that the assessment of D-erythro-neopterin might be an easily available aid for an early evaluation of the immunologic status of a patient at risk for septic complications.
巨噬细胞的激活伴随着2-氨基-4-氧代-6（D-赤藓糖-1'，2'，3'-三羟丙基）-二氢蝶啶（D-赤藓糖新蝶呤）的释放。采用放射免疫分析法测定了21例患者的新蝶呤水平。根据临床病程和结果对患者进行分类。我们发现在观察期的每个评估日，幸存者和非幸存者之间存在高度显著差异。除了持续升高外，与幸存者（31.8±29.9%）相比，预后不良的患者新蝶呤水平超过置信上限（27.4 nmol/L）的百分比始终更高（88.2±28[标准差]%）。我们得出结论，D-赤藓糖新蝶呤的评估可能是一种易于获得的辅助手段，可用于早期评估有发生脓毒症并发症风险患者的免疫状态。
